Effects of different doses of remimazolam besylate on postoperative sedation, pain, and adverse reactions in patients undergoing hysteroscopic surgery.

IF 1.6 3区 医学 Q2 SURGERY
Linjiang Yang, Liang Zhong, Xu Deng, Hao Fang, Siqin Li, Yi Li
{"title":"Effects of different doses of remimazolam besylate on postoperative sedation, pain, and adverse reactions in patients undergoing hysteroscopic surgery.","authors":"Linjiang Yang, Liang Zhong, Xu Deng, Hao Fang, Siqin Li, Yi Li","doi":"10.1186/s12893-025-03017-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hysteroscopy, a minimally invasive gynecological procedure, requires effective sedation for patient comfort and surgical success. Remimazolam Besylate, a new ultra-short-acting benzodiazepine, offers potential for safe sedation, but the optimal dose for postoperative outcomes is unclear. This study evaluated the effects of different doses of Remimazolam Besylate on postoperative sedation, pain, and adverse reactions in hysteroscopic surgery patients.</p><p><strong>Methods: </strong>From June 2020 to June 2022, 90 patients undergoing hysteroscopic surgery under general anesthesia were randomly divided into three subgroups (A, B, C; n = 30 each). Subgroup A received 0.2 mg/kg, Subgroup B received 0.3 mg/kg, and Subgroup C received 0.4 mg/kg of Remimazolam Besylate intravenously during anesthesia induction. Postoperative outcomes, including pain stress mediators (PGE2 and 5-HT), Pain Visual Analogue Scale (VAS) scores, Ramsay Sedation scores, and adverse events, were compared among the subgroups.</p><p><strong>Results: </strong>Subgroup A (0.2 mg/kg) showed significantly higher levels of PGE2 and 5-HT at 2, 12, and 24 h postoperatively compared to Subgroups B (0.3 mg/kg) and C (0.4 mg/kg). VAS scores at 2 and 12 h were higher in Subgroup A, while Ramsay Sedation scores were lower. Subgroup C had a significantly higher incidence of adverse reactions compared to Subgroups A and B.</p><p><strong>Conclusion: </strong>Remimazolam Besylate at a dose of 0.3 mg/kg is optimal for anesthesia induction in hysteroscopic surgery, providing effective sedation, reduced postoperative pain, and a lower incidence of adverse reactions compared to higher doses. This dose is recommended for achieving balanced sedation and safety outcomes.</p>","PeriodicalId":49229,"journal":{"name":"BMC Surgery","volume":"25 1","pages":"278"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12893-025-03017-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hysteroscopy, a minimally invasive gynecological procedure, requires effective sedation for patient comfort and surgical success. Remimazolam Besylate, a new ultra-short-acting benzodiazepine, offers potential for safe sedation, but the optimal dose for postoperative outcomes is unclear. This study evaluated the effects of different doses of Remimazolam Besylate on postoperative sedation, pain, and adverse reactions in hysteroscopic surgery patients.

Methods: From June 2020 to June 2022, 90 patients undergoing hysteroscopic surgery under general anesthesia were randomly divided into three subgroups (A, B, C; n = 30 each). Subgroup A received 0.2 mg/kg, Subgroup B received 0.3 mg/kg, and Subgroup C received 0.4 mg/kg of Remimazolam Besylate intravenously during anesthesia induction. Postoperative outcomes, including pain stress mediators (PGE2 and 5-HT), Pain Visual Analogue Scale (VAS) scores, Ramsay Sedation scores, and adverse events, were compared among the subgroups.

Results: Subgroup A (0.2 mg/kg) showed significantly higher levels of PGE2 and 5-HT at 2, 12, and 24 h postoperatively compared to Subgroups B (0.3 mg/kg) and C (0.4 mg/kg). VAS scores at 2 and 12 h were higher in Subgroup A, while Ramsay Sedation scores were lower. Subgroup C had a significantly higher incidence of adverse reactions compared to Subgroups A and B.

Conclusion: Remimazolam Besylate at a dose of 0.3 mg/kg is optimal for anesthesia induction in hysteroscopic surgery, providing effective sedation, reduced postoperative pain, and a lower incidence of adverse reactions compared to higher doses. This dose is recommended for achieving balanced sedation and safety outcomes.

不同剂量苯磺酸雷马唑仑对宫腔镜手术患者术后镇静、疼痛及不良反应的影响。
背景:宫腔镜是一种微创妇科手术,需要有效的镇静来保证患者的舒适和手术的成功。苯磺酸雷马唑仑是一种新型超短效苯二氮卓类药物,具有安全镇静的潜力,但对术后结果的最佳剂量尚不清楚。本研究评估了不同剂量苯磺酸雷马唑仑对宫腔镜手术患者术后镇静、疼痛和不良反应的影响。方法:选取2020年6月~ 2022年6月全麻下宫腔镜手术患者90例,随机分为3个亚组(A、B、C;N = 30每个)。麻醉诱导时,A亚组静脉给予0.2 mg/kg, B亚组静脉给予0.3 mg/kg, C亚组静脉给予0.4 mg/kg的苯磺酸雷马唑仑。比较亚组间的术后结果,包括疼痛应激介质(PGE2和5-HT)、疼痛视觉模拟量表(VAS)评分、Ramsay镇静评分和不良事件。结果:与B亚组(0.3 mg/kg)和C亚组(0.4 mg/kg)相比,A亚组(0.2 mg/kg)在术后2、12和24 h的PGE2和5-HT水平显著升高。A亚组患者2、12 h VAS评分较高,Ramsay Sedation评分较低。结论:0.3 mg/kg剂量的苯磺酸雷马唑仑是宫腔镜手术麻醉诱导的最佳剂量,可提供有效的镇静作用,减轻术后疼痛,与高剂量相比,不良反应发生率更低。这个剂量被推荐用于达到平衡的镇静和安全结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Surgery
BMC Surgery SURGERY-
CiteScore
2.90
自引率
5.30%
发文量
391
审稿时长
58 days
期刊介绍: BMC Surgery is an open access, peer-reviewed journal that considers articles on surgical research, training, and practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信